TF and cancer: Although their cancer-related modifications, such as a decrease in anti-TF-specific IgM and increased sialylation, have been linked to cancer and prognosis, suggesting usefulness as biomarkers [227,228], there is still insufficient evidence to validate an anti-TF antibody signature in clinical settings [229].